BR112012022680A2 - métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina - Google Patents

métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina

Info

Publication number
BR112012022680A2
BR112012022680A2 BR112012022680A BR112012022680A BR112012022680A2 BR 112012022680 A2 BR112012022680 A2 BR 112012022680A2 BR 112012022680 A BR112012022680 A BR 112012022680A BR 112012022680 A BR112012022680 A BR 112012022680A BR 112012022680 A2 BR112012022680 A2 BR 112012022680A2
Authority
BR
Brazil
Prior art keywords
canine
methods
influenza virus
protect
virus vaccine
Prior art date
Application number
BR112012022680A
Other languages
English (en)
Other versions
BR112012022680B1 (pt
Inventor
Gowda Jayappa Huchappa
S Deshpande Muralidhar
P Lakshmanan Nallakannu
Lee Wasmoen Terri
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112012022680A2 publication Critical patent/BR112012022680A2/pt
Publication of BR112012022680B1 publication Critical patent/BR112012022680B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos para proteger um animal canino e um canino doença, e, uso de uma vacina contra vírus da influenza canina um método para proteger um animal contra doença causada por um patógeno secundário, compreendendo obter uma vacina compreendendo um antígeno contra um patógeno primário, e administração ao animal de uma quantidade imunogenicamente eficaz da vacina contra o patógeno primário.
BR112012022680-0A 2010-03-10 2011-03-08 uso de uma vacina inativada contra vírus da influenza canina BR112012022680B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31238010P 2010-03-10 2010-03-10
US61/312,380 2010-03-10
PCT/US2011/027565 WO2011112593A1 (en) 2010-03-10 2011-03-08 Method for protecting against disease caused by secondary pathogens

Publications (2)

Publication Number Publication Date
BR112012022680A2 true BR112012022680A2 (pt) 2017-04-18
BR112012022680B1 BR112012022680B1 (pt) 2021-03-02

Family

ID=44064623

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022680-0A BR112012022680B1 (pt) 2010-03-10 2011-03-08 uso de uma vacina inativada contra vírus da influenza canina

Country Status (11)

Country Link
EP (1) EP2544717B1 (pt)
JP (1) JP2013522209A (pt)
KR (1) KR20130018681A (pt)
CN (1) CN102791287A (pt)
AU (1) AU2011224507A1 (pt)
BR (1) BR112012022680B1 (pt)
CA (1) CA2791396C (pt)
ES (1) ES2687702T3 (pt)
RU (1) RU2586294C2 (pt)
WO (1) WO2011112593A1 (pt)
ZA (1) ZA201206713B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
CN104411330B (zh) 2012-05-31 2017-02-22 佐蒂斯有限责任公司 用犬呼吸道冠状病毒进行疫苗接种以针对支气管炎博德特菌感染进行保护

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249300B2 (en) * 2000-04-03 2006-02-16 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
KR100570208B1 (ko) 2003-10-15 2006-04-12 주식회사 하이닉스반도체 유기 반사방지막용 광 흡수제 중합체 및 이의 제조 방법과상기 중합체를 포함하는 유기 반사 방지막 조성물
RU2396976C2 (ru) * 2005-10-07 2010-08-20 Пфайзер Продактс Инк. Вакцины и способы лечения собачьего гриппа
AU2006304747B2 (en) * 2005-10-19 2013-10-03 Cornell Research Foundation, Inc. Influenza viruses able to infect canids, uses thereof
EP1941033A2 (en) 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus

Also Published As

Publication number Publication date
CA2791396C (en) 2019-08-27
EP2544717B1 (en) 2018-08-15
WO2011112593A1 (en) 2011-09-15
RU2586294C2 (ru) 2016-06-10
CA2791396A1 (en) 2011-09-15
ES2687702T3 (es) 2018-10-26
ZA201206713B (en) 2013-05-26
EP2544717A1 (en) 2013-01-16
AU2011224507A1 (en) 2012-08-30
CN102791287A (zh) 2012-11-21
KR20130018681A (ko) 2013-02-25
BR112012022680B1 (pt) 2021-03-02
RU2012143152A (ru) 2014-04-20
JP2013522209A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
BR112013010288A2 (pt) método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
BRPI1006452A2 (pt) vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
BR112013020743A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
CO6331297A2 (es) Composiciones adyuvantes novedosas
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
AR090611A1 (es) Vacuna contra mycoplasma hyopneumoniae
CR20150170A (es) Vacunas de inmersión subunidad para peces
PE20151588A1 (es) Vacuna contra el virus del dengue
CR20140069A (es) Formulaciones parenterales de vacunas contra los norovirus
EA201391515A1 (ru) Инактивированная вакцина вируса денге
CO6761354A2 (es) Respuesta inmune potenciada en la especie bovina
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
CL2012002362A1 (es) Sales cristalinas de trometamina y de colina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composicion farmaceutica que las comprende, utiles para el tratamiento de la infeccion por el virus de la hepatitis c.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
CL2012002246A1 (es) Proceso para producir un extracto de alergenos; extracto de alergenos; uso de un extracto de alergenos para tratar alergia a los cacahuetes; composicion farmacéutica que comprende dicho extracto; vacuna que comprende un extracto de alergenos.
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
CL2013000360A1 (es) Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster.
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
BR112016012393A2 (pt) Vacina, e, uso de uma combinação de um vírus prrs atenuado vivo e um antígeno de lawsonia intracellularis inativado
CL2012001995A1 (es) Composicion oral de un agente inmunogénico; metodo para preparar dicha compposicion; metodo de vacunación o de reforzamiento por via oral de un animal contra un patógeno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/03/2011, OBSERVADAS AS CONDICOES LEGAIS.